FOLFIRINOX3 for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have pancreatic cancer that has spread or cannot be removed by surgery
- You have not had chemotherapy for this cancer, or if you had it before surgery it ended more than 12 months ago
- You are healthy enough for daily activities (ECOG score 0 or 1)
- Your heart, liver, and kidney function are within safe limits for this treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding Gembrax (a combination that includes gemcitabine and nab-paclitaxel) before standard FOLFIRINOX works better than FOLFIRINOX alone in people with pancreatic cancer that has already spread. It looks at whether this “step-up first” approach improves results and is still tolerable.
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
This study follows people with pancreatic cancer who are receiving a chemotherapy combination called FOLFIRINOX after surgery. The goal is to see how well the treatment works over time and how it affects long-term survival and cancer recurrence.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.